Navigation Links
Marine scientists warn of potential for spring, summer red tide outbreak in Gulf of Maine
Date:4/22/2009

The potential for an outbreak of the phenomenon called "red tide" is expected to be moderately large this spring and summer, according to researchers at the Woods Hole Oceanographic Institution (WHOI) and North Carolina State University (NCSU).

The finding is based in part on a regional seafloor survey of quantities of Alexandrium fundyense--the microscopic algae notorious for producing a toxin that accumulates in clams, mussels and other shellfish and that can cause paralytic shellfish poisoning (PSP) in humans who consume them.

The research was supported by the National Science Foundation (NSF), NOAA and the National Institutes of Health.

"These studies of Alexandrium, supported by NSF for more than a decade, have resulted in a near-predictive capability for red tides in this region," said David Garrison, director of NSF's Biological Oceanography Program. "Basic research that transitions into products important in management decisions showcases successful interagency partnerships like this one."

Survey maps of the harmful algae are used with computer models that simulate different scenarios of weather and oceanographic conditions to indicate where and in what abundance the toxic algae might be expected in 2009.

The researchers found concentrations of Alexandrium cysts--the dormant seed-like stage of the algae's life cycle--in the Gulf of Maine to be 40 percent lower than the historically high levels observed prior to last year's bloom, but still higher than the level preceding a major regional bloom in spring 2006 that closed shellfish beds from Canada to Massachusetts Bay.

Fall concentrations of Alexandrium cysts are one of the indicators of the magnitude of a potential bloom in spring.

In October 2008, a survey team led by Don Anderson, a biologist at WHOI and principal investigator of the Gulf of Maine Toxicity (GOMTOX) study, spent 10 days collecting seafloor sediment samples between Massachu
'/>"/>

Contact: Cheryl Dybas
cdybas@nsf.gov
703-292-7734
National Science Foundation
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Time record of marine species formation in the Baltic Sea
2. Genes from tiny marine algae suggest unsuspected avenues for new research
3. You dont call, you dont write: Connectivity in marine fish populations
4. Drug used to treat skin conditions is a marine pollutant
5. Dust deposited in oceans may carry elements toxic to marine algae
6. EPA to study Puerto Rico waters and marine habitat
7. New light shed on marine luminescence
8. Nutrient pollution chokes marine and freshwater ecosystems
9. Marine scientists to assess environment before offshore drilling begins in US arctic waters
10. New version of Google Earth features Californias marine protected areas
11. Census of Marine Life and ocean in Google Earth bring ocean information to life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:7/2/2015)... , June 25, 2015 ... of the "Next Generation Biometrics Market by Application, ... report to their offering. The next ... by 2020, at a CAGR of 17.9% between 2015 ... leading application for the market. Safran SA ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... 2012) -- Dr. Darja Marolt, an Investigator at The New ... a study showing that human embryonic stem cells can be ... and potential therapeutic application. Dr. Marolt conducted this research as ... the laboratory of Dr. Gordana Vunjak-Novakovic. The study ...
... "Weather Islands" off the west coast of Sweden. It ... in Sweden. Lars-Ove Loo is the underwater photographer who has ... inventory ahead of the creation of a new nature reserve in ... surface of the sea south of Lyng in the southern Vderarna ...
... 14, 2012) -- Water could change the way we eat. ... Cornwell of the University of Oregon and Anna R. McAlister ... ahead of regular publication by the journal Appetite . ... of 60 young U.S. adults (ages 19-23) about the role ...
Cached Biology News:Begin early: Researchers say water with meals may encourage wiser choices 2
(Date:7/30/2015)... --  Senomyx , Inc. (NASDAQ: SNMX ), a ... develop, and commercialize novel flavor ingredients for the food, ... for the second quarter 2015. "Moving ... track to achieve our commercial and financial goals," stated ... Company. "Since our last quarterly earnings report, our two ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/30/2015)...  Discovery Laboratories, Inc. (Nasdaq: DSCO ) ... $1.0M tranche under a previously awarded Phase II ... up to $3.0 million to support continued development ... potential medical countermeasure to mitigate acute and chronic/late-phase ... initial $1.0 million under this grant in October ...
(Date:7/30/2015)... ... 30, 2015 , ... GEA's Pony™ NS2006L is ... up to 1500 bar. The sanitary design gauge of the NS2006L is well ... The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
Breaking Biology Technology:SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... Copper,s days are numbered, and a new study ... the ubiquitous metal in smart phones, tablet computers, and ... who are seeking smaller, faster devices. As ... size, so do the copper pathways that transport electricity ...
... Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and ... Total revenue for the three months ended September ... period in the prior year. The increase was attributable to ... expenses were $325,000 for the three months ended September 30, ...
... Nov. 10, 2011 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), ... prevent and fight Human Immunodeficiency Virus (HIV) infections, today ... September 30, 2011. GeoVax reported a net ... months ended September 30, 2011, compared to $644,666 ($0.04 ...
Cached Biology Technology:Researching graphene nanoelectronics for a post-silicon world 2Researching graphene nanoelectronics for a post-silicon world 3Interleukin Genetics Reports Third Quarter 2011 Financial Results 2Interleukin Genetics Reports Third Quarter 2011 Financial Results 3Interleukin Genetics Reports Third Quarter 2011 Financial Results 4GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 2GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 3GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 4GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 5
Alexa Fluor 647 anti-mouse Qa-2...
Mouse monoclonal [0.T.81] to Lac1 ( Abpromise for all tested applications). Antigen: Recombinant TrpE fusion protein containing full length E. coli Lac1....
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: